Skip Nav Destination
Issues
1 June 2013
-
Cover Image
Cover Image
![issue cover]()
Composite immunofluorescence of HER2-positive human tumor (BT474 M1) xenografts. Tumor sections from mice treated with saline (controls) were stained for tumor cell nuclei (blue) using Hoechst 33342 dye and blood vessels were stained (red) using anti-mouse CD31 antibody. Tumors from the group treated with fusion construct showed tumor-specific delivery of human granzyme B and upregulation of TUNEL-positive tumor cells compared with controls. For details, see article by Cao and colleagues on page 979.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Reviews
Chemical Therapeutics
Author Choice
Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Nguyen Tan; Maureen Wong; Michelle A. Nannini; Rebecca Hong; Leslie B. Lee; Stephen Price; Karen Williams; Pierre Pascal Savy; Peng Yue; Deepak Sampath; Jeffrey Settleman; Wayne J. Fairbrother; Lisa D. Belmont
The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth
Edward B. Garon; Richard S. Finn; Habib Hamidi; Judy Dering; Sharon Pitts; Naeimeh Kamranpour; Amrita J. Desai; Wylie Hosmer; Susan Ide; Emin Avsar; Michael Rugaard Jensen; Cornelia Quadt; Manway Liu; Steven M. Dubinett; Dennis J. Slamon
Author Choice
Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
Jing Wang; Natalie W. Pursell; Maria Elena S. Samson; Ruzanna Atoyan; Anna W. Ma; Abdelkader Selmi; Wanlu Xu; Xiong Cai; Maurizio Voi; Pierre Savagner; Cheng-Jung Lai
Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities In Vitro and In Vivo
Hua Xie; Mee-Hyun Lee; Feng Zhu; Kanamata Reddy; Zunnan Huang; Dong Joon Kim; Yan Li; Cong Peng; Do Young Lim; Soouk Kang; Sung Keun Jung; Xiang Li; Haitao Li; Weiya Ma; Ronald A. Lubet; Jian Ding; Ann M. Bode; Zigang Dong
Large Molecule Therapeutics
Cancer Therapeutics Insights
Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
Maike Ihnen; Christine zu Eulenburg; Teodora Kolarova; Jing Wei Qi; Kanthinh Manivong; Meenal Chalukya; Judy Dering; Lee Anderson; Charles Ginther; Alexandra Meuter; Boris Winterhoff; Siân Jones; Victor E. Velculescu; Natarajan Venkatesan; Hong-Mei Rong; Sugandha Dandekar; Nitin Udar; Fritz Jänicke; Gerrit Los; Dennis J. Slamon; Gottfried E. Konecny
Author Choice
Downregulation of Hepatoma-Derived Growth Factor Contributes to Retarded Lung Metastasis via Inhibition of Epithelial–Mesenchymal Transition by Systemic POMC Gene Delivery in Melanoma
Han-En Tsai; Guei-Sheung Liu; Mei-Lang Kung; Li-Feng Liu; Jian-Ching Wu; Chia-Hua Tang; Ching-Hui Huang; San-Cher Chen; Hing-Chung Lam; Chieh-Shan Wu; Ming-Hong Tai
Synergistic Anticancer Activity of Arsenic Trioxide with Erlotinib Is Based on Inhibition of EGFR-Mediated DNA Double-Strand Break Repair
Kushtrim Kryeziu; Ute Jungwirth; Mir Alireza Hoda; Franziska Ferk; Siegfried Knasmüller; Claudia Karnthaler-Benbakka; Christian R. Kowol; Walter Berger; Petra Heffeter
Companion Diagnostics & Cancer Biomarkers
Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease
Lai-Ping Zhong; Dong-Wang Zhu; William N. William, Jr; Ying Liu; Jie Ma; Cheng-Zhe Yang; Xiao Yang; Li-Zhen Wang; Jiang Li; Jeffrey N. Myers; J. Jack Lee; Chen-Ping Zhang; Zhi-Yuan Zhang
Tools and Technologies
Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Holly A.F. Stessman; Linda B. Baughn; Aaron Sarver; Tian Xia; Raamesh Deshpande; Aatif Mansoor; Susan A. Walsh; John J. Sunderland; Nathan G. Dolloff; Michael A. Linden; Fenghuang Zhan; Siegfried Janz; Chad L. Myers; Brian G. Van Ness
Advertisement
